+49 6221 137 57 0
Cellzome’s proteomics technologies can be used throughout drug discovery from screening to selectivity profiling of compounds in different cells and also in patient samples. The technologies that Cellzome has developed differ from other traditional methods used in early drug discovery by assessing drug interactions with target proteins in a setting which more closely represents that found in a whole biological system. This allows scientists the opportunity to observe how candidate drugs affect both intended and non-desired targets in a close-to-physiological environment and may pinpoint potential safety issues earlier in the process.
Cellzome AG was acquired by GlaxoSmithKline on May 15, 2012.
Join Mergr to view all 119 acquisitions of life science companies in 2012, including 19 acquisitions by private equity firms, and 100 by strategics.
Out of 60 sectors in the Mergr database, life science ranked 18 in number of deals in 2012. The largest life science acquisition in 2012 was Amylin Pharmaceuticals - which was acquired by Bristol-Myers Squibb for $5.3B.
Join Mergr to view this profile - and discover more life science acquisitions of companies like Cellzome AG.
No obligation. Cancel anytime.